Dr. Adam Snook

Dr. Adam E. Snook received a B.S. in Pharmacology and Toxicology (2001) from the University of the Sciences and a Ph.D. in Immunology and Microbial Pathogenesis (2008) from Thomas Jefferson University. He was a founding member and served as the Director of Antibody Development for 5 years at Invisible Sentinel, Inc., a leading molecular solutions company specializing in food safety and a subsidiary of bioMérieux. He joined the faculty at Thomas Jefferson University in 2013 in the Department of Pharmacology and Experimental Therapeutics where he is studying the mechanisms underlying colorectal cancer tumorigenesis and the interaction between cancer and the immune system to develop new options to prevent or treat gastrointestinal cancers. His work has led to five investigator-initiated clinical trials examining colorectal cancer chemoprevention and cancer vaccines. He has authored over 60 book chapters and papers in prestigious journals, including Cancer Research, Gastroenterology, Journal of Clinical Investigation, and Cancer Cell, and his work has been featured in US News and World Report, Forbes, Reuters, the Washington Post, the New York Times, and others.